NS-304 CTEPH OE

The open-label extension study of NS-304 in patients with chronic thromboembolic pulmonary hypertension (CTEPH)

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222113

Enrollment

Registered

2013-06-13

Start date

2013-06-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic thromboembolic pulmonary hypertension (CTEPH)

Interventions

investigational material(s) Generic name etc : NS-304 INN of investigational material : Selexipag Therapeutic category code : 219 Other cardiovascular agents Dosage and Administration for Investigatio

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with CTEPH who have completed the End-of-Treatment in the AC-065B202 study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Safety	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026